Abstract
Introduction:
Although all of the first-line antihypertensive drugs effectively reduce blood pressure, there are some conditions that may favor the use of angiotensin receptor blockers over others, such as left ventricular hypertrophy, microalbuminuria, renal dysfunction, diabetes, or metabolic syndrome, among others.
Areas covered:
This manuscript reviewed the data supporting the use of candesartan cilexetil in hypertensive population with a special focus on its efficacy and safety. For this purpose, a search on MEDLINE and EMBASE databases was performed. The MEDLINE and EMBASE search included both medical subject headings (MeSH) and keywords including: candesartan OR angiotensin receptor blockers OR renin angiotensin system AND hypertension treatment. References of the retrieved articles were also screened for additional studies. There were no language restrictions.
Expert opinion:
Candesartan, a long-acting angiotensin receptor antagonist, has been shown to be an effective and well-tolerated therapy in the entire spectrum of hypertensive patients, including those at higher risk, such as those with diabetes, metabolic syndrome, left ventricular hypertrophy, or microalbuminuria.
Notes
Malmqvist K, Kahan T, Dahl M. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens 2000;13:504-11 Julius S, Nesbitt SD, Egan BM, Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker. N Engl J Med 2006;354:1685-97 Schaefer F, van de Walle J, Zurowska A, Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens 2010;28:1083-90 Barrios V, Escobar C, Calderon A, Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE Study. J Renin Angiotensin Aldosterone Syst 2006;7:236-42 Mogensen CE, Neldam S, Tikkanen I, for the CALM study group. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4 Edes I, Burgess L, Parow W, Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: a randomized, double-blind, parallel-group study in primary care. Clin Drug Investig 2009;29:293-304 Bonner G, Calder B, Dzyak G, Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. Blood Press Suppl 2008;2:22-30 Yusuf S, Pfeffer MA, Swedberg K, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777-81